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Nabhan et al. reported a 42% response rate in a population of 31 patients with relapsed and refractory B‐cell lymphoma treated with 4 or 6 mg/m^2^ × 5 days, with hematologic toxicity being the major dose‐limiting toxicity (DLT). Mulford et al. reported results from 29 patients with aggressive T‐cell lymphomas, including 4 with transformed mycosis fungoides, treated with clofarabine for 3 consecutive days at doses ranging from 4--20 mg/m^2^. Pleural effusion and prolonged cytopenias were seen at the MTD of 28 mg/m^2^. Five of 29 (17%) patients had responses, including 1 with transformed mycosis fungoides, and 7 patients had disease stabilization. Tumor reductions were reported at all dose levels.

These studies included heavily pretreated patients and demonstrated clinical activity for clofarabine at different doses and schedules. Interestingly, and as we observed, there was no dose response relationship observed in these studies, although conclusions regarding efficacy are limited by small numbers in each cohort. The mechanism of action of clofarabine to block DNA synthesis via inhibition of ribonucleotide reductase and DNA polymerases can potentially overcome drug resistance to conventional cytotoxic agents in patients with relapsed lymphoma. Further studies could explore combinations of clofarabine with other novel agents in relapsed T‐ and B‐cell lymphomas.

Responses to Clofarabine {#onco12361-sec-0016}
========================
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Trial Information {#onco12361-sec-0006}
=================

**Disease**Lymphoma -- non‐Hodgkin**Stage of Disease/Treatment**Metastatic/Advanced**Prior Therapy**More than two prior regimens**Type of Study ‐ 1**Phase I**Type of Study ‐ 2**Modified Fibonacci**Primary Endpoint**Tolerability**Secondary Endpoint**Efficacy**Additional Details of Endpoints or Study Design** **Trial Design and Objectives** In this phase I dose escalation trial, clofarabine was evaluated in patients with relapsed or refractory, low‐grade or intermediate‐grade, B‐cell or T‐cell lymphoma. The starting dose of 10 mg/m^2^ per week was administered IV for 3 consecutive weeks every 28 days. The study objectives were to determine the MTD, characterize and quantify the toxicity profile, and determine the overall response rate of clofarabine administered once a week for 3 weeks and repeated every 4 weeks. **Eligibility Criteria** Eligible patients were over the age of 18 and had a histologically confirmed low‐grade or intermediate‐grade B‐cell or T‐cell lymphoma with measurable disease defined by the Cheson lymphoma criteria \[[13](#onco12361-bib-0013){ref-type="ref"}\]. All enrolled patients must have failed at least one standard chemotherapy regimen, excluding single‐agent rituximab. Patients had to demonstrate an adequate Eastern Cooperative Oncology Group (ECOG) performance status of \<2 and have a life expectancy of \>12 weeks, normal cardiac function (ejection fraction \>45%), and appropriate organ function (absolute neutrophil count \>1000 × 10^9^/L, white blood cell count \>2.5 × 10^9^/L, platelet count \>75 × 10^9^/L, hemoglobin \>9.0 g/dL, total bilirubin \<2.0 mg/dL, aspartate and alanine transaminase \<3 × upper limit of normal, and creatinine \<2.0 mg/dL). Exclusion criteria included a previously untreated B‐cell or T‐cell lymphoma, previous treatment with clofarabine, chronic use of oral high‐dose corticosteroids greater than 20 mg/day prednisone for any medical condition, and prior radiotherapy to the only site of measurable disease. Additional standard exclusion criteria were implemented, including known AIDS‐related or human immunodeficiency virus‐positive lymphoma, active or untreated central nervous system lymphoma, autologous bone marrow or stem cell transplant (within the previous 6 months), and autoimmune thrombocytopenia. Patients were also ineligible if they used an investigational agent within 30 days or any anticancer therapy 3 weeks before study entry, had an active systemic infection, an active secondary malignancy, or were pregnant or lactating. **Treatment Plan** In this phase I trial, patients were enrolled in cohorts of three at a starting dose of clofarabine 10 mg/m^2^ per week for 3 weeks repeated every 28 days. The dose was escalated for subsequent cohorts if no DLT was observed. Please see table for dose escalation design. If a DLT was observed in one of three patients in the cohort, three additional patients were enrolled at that dose level. Dose escalation was then allowed if none of the additional three patients experienced a DLT. If one or more of the additional patients experienced a DLT, the MTD was considered to be exceeded and three additional patients would be treated at the next lower dose if only three patients were treated at that dose level. The MTD was defined as the dose at which fewer than one of six patients experienced a drug‐related DLT, with the next higher dose provoking a DLT in two of six or two of three patients. Additional patients were enrolled if data obtained from previous patients were inadequate because of early death from an unrelated drug toxicity. Patients were treated for a maximum of two cycles before response assessment and were continued on clofarabine until disease progression, unacceptable toxicity, or patient withdrawal. **Supportive Care** Patients were premedicated with acetaminophen 650--1,000 mg orally 30 minutes prior to each dose of clofarabine. Patients received antiviral and Pneumocystis jiroveci prophylaxis. Allopurinol was given at the discretion of the treating physician for patients with extensive tumor bulk at the initiation of treatment. Hematopoietic growth factors were given based on institutional practice. Other supportive care included antiemetics, antibiotics, antidiarrheals, hydration, and blood products as clinically indicated. If patients developed evidence of systemic inflammatory response syndrome or cytokine release, corticosteroids, histamine blockade, and acetaminophen could be administered at the treating physician\'s discretion. **Dose‐Limiting Toxicity** Dose‐limiting toxicities were defined as any grade 4 neutropenia or grade 3 febrile neutropenia that lasted \>7 days; grade 4 thrombocytopenia; grade 3 or 4 nonhematologic toxicity and/or grade 3 or 4 nausea, vomiting, or diarrhea in patients who received optimal treatment with antiemetics and antidiarrheals; grade 4 elevations in alanine, aspartate transaminase, or bilirubin; or treatment delay \>2 weeks because of unresolved toxicity in patients who experienced at least grade 3 thrombocytopenia, grade 4 neutropenia, or any grade 3 nonhematologic toxicity. **Response Assessment** Responses were assessed every two cycles using the 1999 National Cancer Institute (NCI) response criteria \[[13](#onco12361-bib-0013){ref-type="ref"}\]. All patients who achieved a complete response (CR), complete response unconfirmed, or partial response (PR) had their response confirmed at least 2 months after the first documented response. Patients underwent a computed tomography scan if they had a CR or PR at the end of therapy assessment. Bone marrow biopsy and aspirate were obtained in all patients after 2 months and in those who achieved a CR. **Statistical Analysis** The primary objectives included in statistical analyses were MTD, toxicity, and ORR. All patients who entered the study and received at least one dose of clofarabine were evaluated for the safety analyses and determination of MTD. Descriptive statistics were used to summarize safety parameters, including the incidence of adverse events and serious adverse events. Toxicity grading was according to the NCI Common Terminology Criteria for Adverse Events, version 3.0. All patients who enrolled in the study and received at least one dose of clofarabine were evaluated for efficacy using the 1999 NCI International Working Group response criteria for lymphoma. **Investigator\'s Analysis** Drug tolerable, hints of efficacy 
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Drug 1 Generic/Working NameClofarabineTrade NameClolarCompany NameSanofiDrug TypeSmall moleculeDrug ClassAntimetaboliteDoseMilligrams (mg) per square meter (m^2^)RouteIVSchedule of AdministrationWeekly

Patient Characteristics for Phase I Clofarabine {#onco12361-sec-0008}
===============================================

Number of Patients, Male8Number of Patients, Female6StageNot collectedAgeMedian (range): 66 (52--87)Number of Prior Systemic TherapiesMedian (range): 5 (2--8)Performance Status: ECOG0 --- 31 --- 102 --- 13 ---Unknown ---

Primary Assessment Method for Phase I Clofarabine {#onco12361-sec-0009}
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**CTCL** Number of Patients Screened8Number of Patients Enrolled8Number of Patients Evaluable for Toxicity8Number of Patients Evaluated for Efficacy8Evaluation MethodCheson criteria for patients with nodal disease and the modified Severity‐Weighted Assessment Tool and Global Assessment for patients with cutaneous T‐cell lymphomaResponse Assessment PR*n* = 1Response Assessment SD*n* = 4Response Assessment PD*n* =3

 {#onco12361-sec-2309}

**Diffuse Large B‐Cell Lymphoma** Number of Patients Screened4Number of Patients Enrolled4Number of Patients Evaluable for Toxicity4Number of Patients Evaluated for Efficacy4Response Assessment PD*n* =4

 {#onco12361-sec-6339}

**Peripheral T‐Cell Lymphoma** Number of Patients Screened2Number of Patients Enrolled2Number of Patients Evaluable for Toxicity2Number of Patients Evaluated for Efficacy2Response Assessment SD*n* =1Response Assessment PD*n* =1

 {#onco12361-sec-8309}

**Total Patient Population** Number of Patients Screened14Number of Patients Enrolled14Number of Patients Evaluable for Toxicity14Number of Patients Evaluated for Efficacy14Response Assessment PR*n* =1Response Assessment SD*n* =1Response Assessment PD*n* =1

Phase I Clofarabine Adverse Events {#onco12361-sec-0012}
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Assessment, Analysis, and Discussion {#onco12361-sec-0013}
====================================

CompletionStudy terminated before completionTerminated ReasonFunding endedInvestigator\'s AssessmentDrug tolerable, hints of efficacy

 {#onco12361-sec-1013}

Estimates are that in 2017, 72,240 individuals will be diagnosed with non‐Hodgkin lymphoma and that 20,140 will die of the disease \[[1](#onco12361-bib-0001){ref-type="ref"}\]. Analysis of the Surveillance, Epidemiology, and End Results program database suggests that 5‐year overall survival will reach 73% for non‐Hodgkin lymphoma, compared with 51% in 1989. Improvements in chemotherapy and the addition of biological therapy account for this change. Efforts to find good salvage therapies have been underway since the 1980s \[[2](#onco12361-bib-0002){ref-type="ref"}\], \[[3](#onco12361-bib-0003){ref-type="ref"}\], \[[4](#onco12361-bib-0004){ref-type="ref"}\]. In this study we assessed the tolerability and feasibility of an alternative schedule for the antileukemia drug clofarabine as a salvage treatment in non‐Hodgkin lymphoma.

Clofarabine (2‐chloro‐2‐fluoro‐deoxy‐9--D‐arabinofuranosyladenine) is a nucleoside analog that was synthesized with halogenation at the 2‐position of adenine and substitution of a fluorine group at the C‐2 position of the arabinofuranosyl moiety \[[5](#onco12361-bib-0005){ref-type="ref"}\]. It has high affinity for deoxycytidine kinase, and its mechanisms of action are multiple, including inhibition of ribonucleotide reductase, inhibition of DNA synthesis, and incorporation of clofarabine monophosphate into DNA. Clofarabine is a second‐generation purine nucleoside analog that inhibits DNA synthesis and repair. It is currently approved for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia \[[5](#onco12361-bib-0005){ref-type="ref"}\], \[[6](#onco12361-bib-0006){ref-type="ref"}\]. In adults, clofarabine has been investigated in several phase I and II trials as a single agent and in combination for relapsed or refractory acute leukemia \[[7](#onco12361-bib-0007){ref-type="ref"}\], \[[8](#onco12361-bib-0008){ref-type="ref"}\], \[[9](#onco12361-bib-0009){ref-type="ref"}\], \[[10](#onco12361-bib-0010){ref-type="ref"}\], \[[11](#onco12361-bib-0011){ref-type="ref"}\]. These studies have shown that clofarabine has activity and an acceptable safety profile in patients with hematological malignancies.

However, clofarabine use in lymphoproliferative disorders has been limited because of myelosuppression and inability for dose escalation. For example, in a phase I/II trial evaluating clofarabine in relapsed or refractory non‐Hodgkin lymphoma, the maximum tolerated dose (MTD) was noted to be 4 mg/m^2^ based upon the dose‐limiting toxicity of myelosuppression \[[12](#onco12361-bib-0012){ref-type="ref"}\]. This dose is significantly less than the doses used in the acute leukemia trials in which myelosuppression was considered acceptable. Therefore, a phase I clinical trial was conducted to investigate the safety and efficacy of clofarabine starting at a dose of 10 mg/m^2^ per week.

Clofarabine was approved by the U.S. Food and Drug Administration for the treatment of pediatric acute lymphoblastic leukemia in 2004. Subsequent studies showed that clofarabine triphosphate can increase levels of intracellular ara‐CTP, leading to combination trials with ara‐C in patients with myeloid leukemias. In phase I studies, the maximum tolerated dose of clofarabine given as a 1‐hour infusion daily for 5 days was 40 mg/m^2^ per day. The dose‐limiting toxicity was hepatotoxicity.

Clofarabine continues to play a major role in the treatment of acute myeloid leukemias. Induction regimens containing clofarabine are associated with a high complete response rate and lower morbidity, and the drug is active in the salvage setting in both young and elderly patients. Additionally, clofarabine is used as a conditioning regimen prior to transplantation. The most frequently used dosing regimen for acute myeloid lymphoma is 30 mg/m^2^ weekly for 5 consecutive days.

In this study, clofarabine was dosed on a once‐weekly basis. There was no MTD seen with this schedule. There was no demonstrated activity for B‐cell lymphomas when dosed on this schedule, although the number of patients treated was small and all were refractory to other therapies. A signal of activity was seen in T‐cell lymphomas, with one partial response in a patient with cutaneous T‐cell lymphoma and several patients with T‐cell lymphomas who achieved stabilization of their disease. Based on this study enrolling a small number of patients with refractory disease and using a weekly dosing schedule, it is unclear whether clofarabine has meaningful clinical activity in T‐cell lymphomas. Activity was also observed by Mulford et al., who reported results from 29 patients with aggressive T‐cell lymphomas, including 4 with transformed mycosis fungoides treated with clofarabine for 3 consecutive days at doses ranging from 4--20 mg/m^2^ \[14\]. Pleural effusion and prolonged cytopenias were seen at the MTD of 28 mg/m^2^. Five of 29 (17%) patients responded, including 1 with transformed mycosis fungoides, and 7 patients had disease stabilization. Tumor reductions were reported at all dose levels.

This study enrolled a heterogeneous group of patients with refractory disease. The median was five prior regimens. A signal of activity was seen in patients with cutaneous T‐cell lymphomas---but only a single partial response. There was no response in patients with B‐cell lymphomas. There was no apparent dose response relationship, and the sole response occurred at the lowest dose. Clofarabine may be an active drug in T‐cell lymphomas and could be further explored in patients who have not had extensive prior therapy.

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT00338494](https://clinicaltrials.gov/ct2/show/NCT00338494)
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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[^1]: Abbreviations: CR, complete response; CTCL, cutaneous T‐cell lymphoma; DLBCL, diffuse large B‐cell lymphoma; PET, positron emission tomography; PR, partial response; PTCL, peripheral T‐cell lymphoma; SLL, small lymphocytic lymphoma.

[^2]: Abbreviations: CMV, cytomegalovirus; GI, gastrointestinal; HSV, herpes simplex virus; N/V, nausea and vomiting.
